BHARATHIDASAN UNIVERSITY

Tiruchirappalli- 620024, Tamil Nadu,
India

Programme: M.Sc., Biomedical Science
(5 Year Integrated Program)

Course Title : Stem Cell Biology and Regenerative Medicine
Course Code : BM59C17

Unit-IV
Cancer Stem Cells

Dr. K. PREMKUMAR
Professor
Department of Biomedical Science

Cancer Stem Cells - Role in Solid Tumors

- **Definition**:
  - Subpopulation of cancer cells with self-renewal ability and differentiation into heterogeneous tumor cells.
  - Example: CSCs in breast cancer express markers like CD44+CD24-/low.

- **Characteristics of CSCs in Solid Tumors:**
  - **Tumor initiation:** Capable of forming new tumors when transplanted.
  - **Resistance to therapies:** Enhanced DNA repair mechanisms and quiescence protect CSCs.
  - **Hypoxia adaptation:** CSCs thrive in low oxygen conditions, such as in the tumor microenvironment.

- **Examples in Solid Tumors:**
  - Glioblastoma (CD133 as a marker).
  - Pancreatic cancer (ALDH1 expression).
  - Colon cancer (EpCAM+CD44+ markers).

- **Role in Tumor Progression:**
  - Drives metastasis by epithelial-to-mesenchymal transition (EMT).
  - Contributes to tumor heterogeneity and recurrence.

Control of CSC Migration and Invasion

- **Mechanisms Driving CSC Migration and Invasion:**
  - **Epithelial-Mesenchymal Transition (EMT):** Loss of adhesion (E-cadherin downregulation) and increased motility (N-cadherin expression).
  - **Matrix Metalloproteinases (MMPs):** Degrade extracellular matrix, aiding invasion (e.g., MMP-2 and MMP-9).
  - **Cytokines and Chemokines:** CXCL12/CXCR4 axis promotes migration.
- **Strategies for Controlling CSC Migration:**
  - **Inhibition of EMT:**
    - Example: Targeting TGF-β signaling to prevent EMT.
  - **Blocking MMP activity:**

    Example: Marimastat, an MMP inhibitor
  - **Disrupting chemokine signaling:**
    - Example: AMD3100 inhibits CXCR4, reducing metastasis in breast cancer.

Implication of Cancer Stem Cells for Therapy

- **Challenges Posed by CSCs in Therapy:**
  - Resistance to conventional chemotherapy and radiation therapy.
  - Recurrence and metastasis due to surviving CSCs.

- **Emerging Therapeutic Strategies:**
  - **CSC-specific targeting agents:**
    - Example: Salinomycin selectively kills breast CSCs.
  - **Combination therapies:**

    Combining CSC inhibitors with conventional drugs to target bulk tumor and CSCs
  - **Immunotherapy:**
    - Enhancing immune response against CSC markers like CD133.

Cytokines as a Survival Factor in Cancer Stem Cells

- **Role of Cytokines in CSC Survival:**
  - **IL-6:** Promotes STAT3 signaling, enhancing survival and self-renewal.
  - **TGF-β:** Induces EMT and maintains stemness.
  - **IL-8:** Facilitates CSC migration and angiogenesis
- **Example Studies:**
  - High IL-6 levels correlate with poor prognosis in ovarian cancer.
  - TGF-β inhibitors reduce CSC populations in pancreatic cancer models.
- **Targeting Cytokine Signaling in Therapy:**
  - **Blocking STAT3 signaling:**
    - Example: Ruxolitinib inhibits JAK/STAT pathway, reducing CSC survival.
  - **Neutralizing antibodies:**
    - Example: Anti-IL-6 antibodies suppress CSC proliferation.

Exploiting Cancer Stem Cell Differentiation for Tumor Therapy

- **Concept:**
  - Forcing CSCs to differentiate reduces their stemness, making them more susceptible to conventional therapies.
- **Strategies to Induce Differentiation:**
  - **Retinoic acid therapy:**
    - Induces differentiation in neuroblastoma CSCs.
  - **Epigenetic modulators:**
    - Example: Histone deacetylase (HDAC) inhibitors like Vorinostat induce differentiation in glioblastoma CSCs.
- **Advantages:**
  - Reduced recurrence and metastasis.
  - Enhanced effectiveness of chemotherapy.

Targeting Autocrine Survival Signals in CSCs

- **Autocrine Signaling in CSCs:**
  - CSCs produce growth factors and cytokines that bind to their own receptors to support survival and proliferation.
  - Example: VEGF produced by CSCs in glioblastoma enhances angiogenesis and CSC survival.
- **Therapeutic Approaches:**
  - **Disrupting autocrine loops:**
    - Example: Bevacizumab (anti-VEGF antibody) in glioblastoma.
  - **Inhibiting growth factor receptors:**

    Example: Erlotinib targets EGFR signaling in lung cancer CSCs
- **Preclinical and Clinical Evidence:**
  - Preclinical studies show reduced CSC populations with autocrine signal inhibitors.
  - Ongoing clinical trials evaluating efficacy in combination therapies.

1. CSCs play a pivotal role in tumor initiation, progression, and resistance.
2. Therapeutic strategies targeting CSCs must focus on:
    - Inhibiting survival pathways (cytokines, autocrine signaling).
    - Inducing differentiation.
    - Overcoming therapy resistance.
3. Future research should prioritize integrating CSC-specific therapies into clinical practice.